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High prevalence of a rare hepatitis C virus in patients treated in the
same hemodialysis unit: Evidence for nosocomial transmission of HCV.
Hepatitis C virus (HCV) is a major cause of hepatitis among patients
treated with maintenance hemodialysis. Blood transfusion appears to be
the primaly risk factor, but nosocomial transmission of HCV in the dialytic
environment has been hypothesized. We addressed this issue by analyzing
the individual variation of genomic sequences of HCV in 28 patients on
chronic hemodialysis (HD) from the same department and 25 environ-
mentally unrelated patients with HCV-related liver disease. Genome
variations of HCV were studied by single strand conformation polymor-
phism (SSCP) analysis of polymerase chain reaction products obtained
from the 5'-untranslated region of the viral genome and by sequence
analysis. Six different SSCP patterns were identified in HD patients versus
16 in control patients. Among HD patients the three more frequent SSCP
patterns accounted for 85% of observations, while in the control group
each pattern was found in 4 to 12% of patients. The ability of SSCP to
discriminate sequence variation was proven by sequence analysis which
confirmed identity/diversity of sequences selected by SSCP. Moreover,
sequence analysis permitted a recognition of the most frequent genome
observed in HD patients as a type 4 HCV, which is considered to be rare
in the Italian population. The relative homogeneity of HCV variants in
HD patients treated in the same HD and the high prevalence in this unit
of a rare viral variant support the possibility of a nosocomial transmission
of HCV in the dialytic environment.
A high prevalence of antibodies to hepatitis C virus (HCV)
(ranging from 2% to 59%) has been reported in hemodialysis
patients (HD) [1—17]. The prevalence of anti-HCV antibodies
increases significantly with age and duration of hemodialysis.
Most cases of HCV infection are thought to be related to blood
transfusions, intravenous drug addiction, or HIV infection, but
analysis of these risk factors appears to leave a residual unac-
counted risk directly related to the duration of exposure to dialytic
treatment [3, 6, 8, 9, 15, 18, 19]. An increased prevalence of
anti-HCV has also been reported in non-transfused HD patients
without identifiable risk factors [3, 6, 8, 9, 18, 20—25]. Theoreti-
cally, the repeated exposure to extracorporeal circulation and the
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immunodepression related to the uremic condition [26] may
confer to HD patients a high risk of parenteral infection other
than blood transfusion and different, as yet undefined, parenteral
routes of transmission of HCV may exist in the hemodialysis
setting. In fact, recent reports outline that HCV-negative patients
who shared dialysis machines with HCV-positive patients sero-
converted within a short period [24].
Diagnosis of HCV infection is based on assays able to detect the
presence of antibodies directed against the virus [27, 28], but no
serological test is presently available to detect antigenemia.
Therefore, detection of the viral genome by reverse transcription
and polymerase chain reaction (PCR) is the only available pro-
cedure to diagnose viremia and identify infectious subjects [29—
32].
Low fidelity of replication catalyzed by viral RNA-dependent
RNA polymerases, attributed to a lack of proof reading activity
[33], confers a high degree of variability to the HCV genome.
Natural evolution has caused part of this heterogeneity to become
fixed in subsets of the viral population, giving rise to sequence
polymorphism which has been used for identification of viral
subtypes. HCV genome typing by analysis of PCR products [34,
351 has been used to establish correlations with the clinical
evolution of the infection, to study the distribution of HCV types
and to analyze modes of transmission. The predominance of a
viral type in a human population or geographical area may,
however, limit the use of typing to analyze transmission, and more
sensitive techniques like nucleotide sequence analysis and indirect
methods able to resolve sequence variation are required for
detection of sequence variants, thus allowing an individual iden-
tification of the viral genome.
To evaluate the heterogeneity of HCV sequences in HD
patients we employed single strand conformation polymorphism
(SSCP) analysis [36, 37], a method based on the electrophoretic
analysis of denatured PCR products able to resolve sequences
differing for single nucleotide substitutions. Comparing the num-
ber and type of HCV SSCP variants in HD patients and in a
control group of environmentally unrelated patients with HCV-
associated chronic liver disease we address the issue of HCV
transmission in the HD unit.
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Methods
Patients
The study was performed on 48 patients on chronic HD
treatment after informed consent was obtained. Twenty-seven
were men and 21 women with a mean age of 55.6 2 years (range
27 to 81). Five patients were chronic carriers of HBsAg. All
patients were being treated with maitenance MD in our unit, with
a mean duration of HD treatment of 111.2 13.2 months (range
7 to 309 months). MD was performed three times weekly, each
time for four hours, with cuprophane, polymethilmetacrylate,
polysuiphone or cellulose acetate membranes. Hospital records of
each patient were reviewed for medical history, HCV serology
(available from April 1990), liver biochemistry and blood trans-
fusions. All patients shared the same monitors. Isolation measures
were implemented for anti-HCV positive patients from the end of
1992, before the beginning of the present study. Twenty-five
environmentally unrelated HCV-RNA positive patients with di-
agnosis of HCV-related chronic liver disease based on clinical,
serological and histological criteria, and no evidence of renal
disease served as controls. All individuals examined, HD patients
and controls, are Italians from different regions of Italy, without
significant differences between the two groups, and all have been
living in the area of Milan for several years.
Serum samples were collected in April and October 1993,
divided into aliquots and stored at —70°C for HCV-RNA and
anti-HCV assays.
Anti-HCV antibodies
Anti-HCV were tested with EIA H (Abbott Laboratories, North
Chicago, IL, USA) which detects antibodies to three different
regions of HCV: C100-3 (non-structural region 4), C33 (non-
structural region 3) and C22 (putative core protein).
HCV-RNA
RNA extraction was performed with the acid guanidinium
thiocyanate-phenol-chioroform method [38] from 500 d serum
with the addition of 1 jig glycogen as a carrier prior to isopropanol
precipitation. Complementary DNA (cDNA) synthesis (Perkin-
Elmer, Cetus RNA-PCR kit) was primed from the core region of
HCV-RNA using the external common reverse primer described
by Okamoto et a! [34]. Nested PCR was performed using primer
sequences located in 5' untranslated region (5'UTR) [39]. The
first round of PCR (25 cycles, annealing temperature 50°C) was
performed with primers F (5'-CCCCTGTGAGGAACTACT-
GTC-3') and R (5'-TGCACGGTCTACGAGACCTCC-3') and
the internal PCR (30 cycles, annealing temperature 55°C) with
primers Fi (5'-CGCAGAAAGCGTCTAGCC-3') and Ri (5'-
ACCCTATCAGGCAGTACC-3') giving rise to a 236 bp product
(nt —275 to 40). All PCR reactions were performed in a final
volume of 50 pJ in the presence of 2.0 jimol/liter MgC!2, 0.2
jimol/liter of each primer, 1/4 of the cDNA reaction and 2.5 U of
Taq polymerase. Strict precautions to prevent contamination were
adopted; negative controls were introduced during RNA extrac-
tion and processed throughout cDNA synthesis and PCR. Ampli-
fied products were examined on ethidium bromide stained aga-
rose gels.
Table 1. Clinical data of 48 hemodialysis patients divided according
their HCV-RNA status
PCR positive
(N=28)
PCR negative
(N=20) P
Age years
HD age months
High ALT/AST in
52.4 2.5
(27—81)
151.9 17.5
(20—309)
11
60.1 3.1
(28—77)
54.1 11.6
(7—190)
6
0.06
0.0001
NS
history (39%) (30%)
Blood transfusions 21
(75%)
5
(29%)
0.007
Data were compared by Student's t-test.
SSCP analysis
PCR products from HCV-RNA positive individuals were dena-
tured (usually 1/10 of the reaction volume) for 5' at 95°C in the
presence of a denaturing buffer (92% formamide, 20 mrvi EDTA,
0.05% bromophenol blue) and loaded on non-denaturing 10%
polyaciylamide (acrylamide/bis-acrylamide 38.5:1.5) minigels (Mini
Protean, Biorad). Gels were run for three hours at 100 volts
constant voltage in Tris-Borate-EDTA buffer and silver stained.
SSCP patterns were assessed by consensus of two independent
observers and arbitrary denomination was used to identify differ-
ent SSCP patterns. Reproducibility of SSCP patterns was checked
by analyzing a second independent PCR product for each subject.
Sequence analysis of SSCP variants
Identity/diversity of sequences associated with SSCP patterns
was assessed by sequencing the amplified 5'UTR of HCV from 10
patients and controls with different SSCP patterns (3 with pattern
C, 2 each with patterns F, I and N, one with pattern E). PCR
products from these patients were cloned in plasmid pCR"II
(Invitrogen, San Diego, CA, USA). Before sequencing the DNA
from six recombinant clones from each patient was subject to
amplification and SSCP: in each patient at least four of six clones
gave rise to a SSCP pattern identical to the original one and one
of these clones for each patient was analysed by automatic
sequencing (DNA Sequencer 373A, Applied Biosystems, San
Jose, CA, USA).
Results
Among the 48 patients studied PCR showed a positivity for
HCV-RNA in 28 cases (58.3%). Twenty-four of them (85.7%)
were positive for anti-HCV at EIA II and one patient had a
seroconversion two months after PCR determination.
The 28 patients with positivity for HCV-RNA by PCR had a
longer dialysis age than negative patients and 21 of them had
received blood transfusions in their clinical history (Table 1).
None of them was HIV-positive or drug addict. Only one of the
five patients who seroconverted to anti-HCV during the time of
observation with EIA II test (1991—93) had received blood
transfusions. No significant differences were observed between
PCR positive and negative patients for history of high ALT/AST
levels.
SSCP analysis of PCR products obtained from HD HCV-RNA
positive patients and from patients of the control group allowed us
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Fig. 1. SSCP electrophoretic patterns observed in HD patients and in controls. (a) The 18 different patterns characterized in the two groups. (b) SSCP from
18 of the HD patients run on two gels, allowing to detect identity of patterns in individual patients. 1 denotes molecular weight marker 1X174 HaeIII
digest which was used to uniformate electrophoretic migration of different gels.
SSCP patterns
to distinguish 18 different patterns associated with sequence
variation in the 5' untranslated region of HCV genome (Fig. 1 a,
b). A graphic representation of SSCP patterns distribution is
shown in Figure 2. In the HD group six different SSCP patterns
Fig. 2. Distribution of SSCP patterns
characterized in 28 HD patients (•) and in 25
environmentally unrelated HCJ/-positive controls
(s).
were observed: pattern Cwas shared by 11 patients (39%), pattern
F by 9 patients (32%), pattern B by 4 patients (14%), pattern E
was found in 2 patients (7%) and patterns A and M were present
in one patient each. In the control group 16 different patterns
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HCV genome
-138 -122 -99 -63
I I
GTCCTTTCTTGGATCAACCCGCTCAATGCCTGGAGATTTGGGCGTGCCCCCGCGAGACTGCTAGCCGAGTAGTGTTGGGTCGCGAAAGGCA —A A
A C—A A-
A A—T C—CC
A
A
A- C T
T
pattern C (Df)
pattern C (Rd)
pattern C (By)
pattern E (Dz)
pattern F (Pg)
pattern F (Fz)
pattern I (Mf)
pattern I (Sp)
pattern N (Fr)
pattern N (Pd)
Fig. 3. Sequence analysis of part of the 5-untranslated region of HCVgenome in 10 subjects selected by SSCP analysis. A scheme of the HCV genome with
localrzation of the amplified region is shown at the top of the figure. Nucleotide sequences from —242 to —63 according to the numeration adopted by
Bukh et al [39] were aligned to a prototype lb HCV sequence characterized by Kato et al [40]. Only nucleotides diverging from the reference sequence
are shown for the ten clones. An asterisk denotes a single nucleotide deletion.
were characterized; the most fr equent SSCP pattern, G, was
found in 3 patients (12%), patterns B, F, I, N and T were present
in 2 patients each (8%), while patterns C, D, H, L, M, 0, P, Q,R
and S were found each in only one patient (4%). The prevalence
of patterns C and F was significantly different between the two
groups (P = 0.0026 and 0.043, respectively, Fisher exact test).
Identity of SSCP in individual HD patients is demonstrated in
Figure lb in which two gels with the electrophoretic pattern of 18
HD patients are shown. SSCP patterns proved to be reproducible
on different PCR products amplified from the same patient. PCR
products selected for sequencing were also reassessed in a sample
obtained six months after the initial analysis, and in each case the
pattern obtained was identical to the original one.
Validation of the information acquired by SSCP was obtained
by sequence analysis of PCR products. Three products showing
SSCP pattern C, two with pattern F and one with pattern E from
the group of HD patients and two each with patterns I and N from
the group of controls were analyzed. In each case the obtained
nucleotide sequence confirmed identity/diversity of SSCP pat-
terns. Alignement of these sequences to the HCV sequence
characterized by Kato [40] is shown in Figure 3. Comparison with
previously characterized HCV isolates and classification accord-
ing to Simmonds [35, 41, 42] allowed to identif' the sequence
associated to pattern C as belonging to type 4 HCV [35], sequence
associated to pattern E to type 2a [43] and sequences with
patterns F, I and N to type lb [40].
Discussion
In accordance with previous investigations the current study
shows a high prevalence of HCV infection in HD patients.
HCV-RNA detection by PCR confirmed that most anti-HCV
positive patients are viremic and have to be considered as
infectious. In three patients HCV-RNA was found in the absence
of detectable antibodies to HCV. Since delayed seroconversion to
anti-HCV in HD patients has been previously reported [19, 44] a
later seroconversion cannot be excluded.
The reasons underlying the high prevalence of HCV infection
in HD patients are not completely defined, Blood transfusions are
likely to have played a major role before the use of anti-HCV
assays and before the introduction of recombinant erythropoietin
UTR
1: C El :JNS1I NS2 NS3 NS4 NS5
-242 -235 -167
I I
GTGTTGTGCAGCCTCCAGGACCCCCCCTCCCGGGAGAGCCATAGTGGTCTGCGGAACCGGTGAGTACACCGGAATGCCAGGACGACCGG
A C—G—T
A
A
— C—
— C—
— C—
— C—
pattern C (Df)
pattern C (Ad)
pattern C (By)
pattern E (Dz)
pattern F (Pg)
pattern F (Fz)
pattern I (Mf)
pattern I (Sp)
pattern N (Fr)
pattern N (Pd)
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for the treatment of anemia in HD patients [45]. At present,
however, several observations agree in indicating the presence of
routes of transmission other than transfusion in these patients [9,
11, 15, 18, 19].
Given the considerable heterogeneity of HCV genome, we
assumed that if HCV infection is frequently transmitted within the
dialysis unit, viruses found in HCV-positive HD patients treated
for a prolonged time in the same unit should be more homoge-
neous than those isolated from a population of environmentally
unrelated HCV-positive individuals. In this work we employed
SSCP for the analysis of a region of HCV genome in order to
obtain, through the SSCP pattern, a genetic "signature" or
"fingerprint" able to individually identify HCV sequences. We
analyzed the 5'-untranslated region of the HCV genome. This
region is highly conserved within the viral genome, thus optimiz-
ing the diagnostic detection of viral sequences [29, 39], but still is
characterized by a degree of heterogeneity, often allowing inter-
individual discrimination. Other, less conserved regions of the
viral genome may accumulate significant variation during the
chronic infection of a single individual in a relatively short period
of time [46, 47] and thus are less useful in the evaluation of viral
transmission, unless extensive sequencing of the genome is per-
formed. SSCP analysis permits detection of sequence variation on
the basis of differences in the electrophoretic mobility of short
denatured DNA fragments. The method is highly sensitive and is
able to detect the majority of mutations [48]. Though it is not
possible to directly relate SSCP patterns to type and location of
sequence variation in the fragment examined, different SSCP
patterns consistently point Out different sequences. Sequence
analysis in ten patients and controls confirmed the usefulness of
SSCP to detect sequence identity or diversity: five different SSCP
patterns (C, F, E, I, N) were associated to five different sequences
while sequences giving rise to identical SSCP patterns proved to
be identical (Fig. 3).
Among 28 HD patients positive at PCR, only six different SSCP
patterns were observed; three of these patterns accounted for
85% of the observations. In contrast, SSCP patterns were more
heterogeneous in the control group with 16 different patterns
found in 25 patients, the most frequent pattern being found in
only 3 (12%) patients. The comparison of the two groups showed
that the more frequent patterns found in HD patients are not
common in the general population. In fact, pattern C, the most
represented in the HD group, was 10 times more frequent in HD
than in control group while patterns F and B, accounting for 46%
of observations in HD patients, were found in 16% of controls.
Reproducibility of SSCP patterns on different PCR products from
the same patient ruled out the possibility of artifactual heteroge-
neity introduced by misincorporation of nucleotides during PCR
[49], and stability of SSCP patterns over a six month period
confirmed the relative conservation of the 5'UTR of HCV [47].
Sequence analysis of cloned PCR products demonstrated that
SSCP pattern C, present in 39% of HCV positive HD patients,
was associated with a sequence strongly related to type 4 HCV
[35]. This hepatitis C virus type, common in the Middle East and
Africa, is rare in Europe [39, 42, 50] and, to our knowledge, has
not yet been reported in Italy. SSCP pattern F in HD patients and
I and N in control patients are associated with the common type
lb HCV which is the prevalent type in Italy [51]. The relative
homogeneity of HCV variants and types in HD patients, also
confirmed by the unexpected predominance in this group of a rare
viral genome, is intriguing and strongly suggests the possibility of
transmission of HCV through the HD environment. The distri-
bution of HCV SSCP patterns related to patients' history is also
consistent with this hypothesis: pattern C is more common in
patients with longer dialysis age, indicating the possibility of past
epidemics, while patterns F and B are found in patients with a
shorter dialysis age.
Which are the possible modes of transmission of HCV infec-
tions in a HD unit? A lack of careful surveillance of hygienic
routines and of sterilization procedures might facilitate the spread
of the infection. On the other hand, the virus might also contam-
inate the dialysis fluid. We and others have recently detected
HCV by PCR in the dialysate and blood-ultrafiltrate of HCV
positive patients [52 and M. Lombardi et al, personal comunica-
tion]. Type and duration of dialysis, type and preparation of
membranes, transmembrane pressures and/or incorrect use of
heparin may influence the contamination of dialysis fluid. Tests
for the detection of HCV on dialysis machines have been sug-
gested to acquire evidence for one of the possible routes for
nosocomial transmission of the infection [23].
In conclusion, a significant homogeneity of types and variants of
HCV was found in a dialysis unit with a high prevalence of HCV,
supporting the hypothesis of routes of infection within the dialysis
unit. On the basis of these data, and in agreement with a report on
the reduction of new cases of HCV infection after segregation of
HCV-positive patients [22], we feel that the use of a dedicated
area and dialysis monitors for HCV positive patients as well as
accurate chemical sterilization of monitors after each session are
useful procedures to control HCV transmission in dialysis envi-
ronments.
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